Skip to main content

Want a detailed portfolio tracker?

CATX
AMEX
$2.93

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Website: https://www.perspectivetherapeutics.com
68 analysts
Buy
Target: $12.93 (+342.05%)

Market Cap

$367M

EPS 5Y CAGR

+89.93%

FCF 5Y CAGR

+103.83%

Free Cash Flow Yield

-29.28%

Price Chart

Valuation
Market Cap$367M
Forward P/E25.71
P/S594.22
P/B1.00
Profitability
Gross Profit (TTM)-$91M
EBITDA-$116M
Operating Margin-37212%
EPS-$1.37
Financial Health
Debt-to-Equity0.5%
Free Cash Flow Yield-29.28%
Growth & Risk
EPS 5Y CAGR+89.93%
FCF 5Y CAGR+103.83%
Beta (5Y)1.52
Sharpe Ratio0.14